Role of Group 1B Phospholipase A2 in Diet-Induced Hyperlipidemia and Selected

Total Page:16

File Type:pdf, Size:1020Kb

Role of Group 1B Phospholipase A2 in Diet-Induced Hyperlipidemia and Selected Role of Group 1B Phospholipase A2 in Diet-induced Hyperlipidemia and Selected Disorders of Lipid Metabolism A dissertation submitted to the Graduate School at the University of Cincinnati in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Pathobiology and Molecular Medicine of the College of Medicine By Norris Isaac Hollie, II B.S., B.A. Oakwood University, Huntsville, Alabama July 23, 2013 Committee Chair: David Y. Hui, Ph.D. Abstract As obesity rates increase in developed nations, the prevalence of other obesity-related metabolic disorders such as hyperlipidemia, atherosclerosis, and non-alcoholic fatty liver disease (NAFLD) has also increased drastically. A greater understanding of the pathobiology and molecular mechanisms of these disorders becomes increasingly relevant. Recent studies demonstrated that certain alleles of the pancreatic group 1B phospholipase A2 (PLA2G1B) are associated with increased obesity and that Pla2g1b-deficient (Pla2g1b-/-) mice are protected against diet-induced obesity and diabetes. Furthermore, supplying mice with lysophosphatidylcholine (LPC), the enzymatic product of Pla2g1b, causes hyperglycemia and insulin resistance, which are risk factors for hyperlipidemia, atherosclerosis, and NAFLD. Thus, Pla2g1b may play a role in the development of these obesity-related diseases and inhibiting Pla2g1b and/or LPC may change the progression of these metabolic disorders. The goal of the first part of this dissertation was to identify a Pla2g1b-mediated protection against hyperlipidemia. Findings from these studies indicate that Pla2g1b-/- mice are protected against high fat diet-induced hyperlipidemia and gain less weight than Pla2g1b+/+ controls due to decreased very-low-density lipoprotein (VLDL) production and increased postprandial triglyceride-rich lipoprotein clearance. Further results indicate that supplying LPC stimulates VLDL production in both Pla2g1b-/- and Pla2g1b+/+ mice and that LPC is directly used as a substrate to make VLDL-triglyceride (TG). Taken together, these findings indicate that inhibition of luminal Pla2g1b may be a viable strategy to decrease hyperlipidemia in vivo. The goal of the second part of this dissertation was to identify a mechanism of LPC- mediated inhibition of hepatic oxidative function. Pla2g1b-/- mice have decreased plasma LPC and increased hepatic oxidation that is inhibited by intraperitoneal injection of LPC by an Page ii unknown mechanism. Findings indicate that though low micromolar concentrations of LPC decrease the mitochondrial membrane potential, oxidation rate remains equal to controls up to incubation with 80 µM LPC. However, when isolated mitochondria or hepatocytes are supplied with 100 µM LPC, decreased substrate-stimulated oxidation and increased mitochondrial permeability are observed. These findings indicate that LPC plays a major role in the maintenance of hepatic mitochondrial integrity and function and that low micromolar changes in intra- and extracellular LPC concentration can greatly affect hepatic oxidation rate. The goal of the third part of this dissertation was to identify a Pla2g1b-mediated protection against atherosclerosis and NAFLD. Findings indicate decreased obesity, VLDL-TG, VLDL-cholesterol, low-density lipoprotein-cholesterol, and hepatomegaly in Pla2g1b-/-/Ldlr-/- mice compared to Pla2g1b+/+/Ldlr-/- controls. Findings also suggested decreased atherosclerotic lesion size in Pla2g1b-/-/Ldlr-/- mice. Taken together, the findings from this dissertation have three implications in the field of metabolic research. First, these studies indicate a vital role for Pla2g1b and LPC in modulating hepatic function. Regardless of the Pla2g1b status of experimental animals, the mechanisms of LPC action appear intact. Secondly, these studies indicate that inhibition of Pla2g1b provides protection against diet-induced obesity in two diverse murine models. Thirdly, decreased VLDL- TG is described as a hallmark of inhibition of Pla2g1b. The development of a single drug to inhibit the action of PLA2G1B would likely lead to improvements in obesity, diabetes, hyperlipidemia, and potentially atherosclerosis. Page iii Copyright Notice This dissertation is based, in part, on a published manuscript. Part of this research was originally published in the Journal of Lipid Research. Hollie NI and Hui DY. Deficiency of group 1b phospholipase A2 protects against diet-induced hyperlipidemia. J Lipid Res. 2011; 52: (11) 2005-2011. © the American Society for Biochemistry and Molecular Biology. Page iv Acknowledgements This work was supported by Grant DK069967 from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institute of Health. The author was a fellowship recipient of grants F31HL110527 from the National Heart, Lung, And Blood Institute, Grant Number T32GM063483 from the National Institute of General Medical Sciences, and Grant Number 11PRE7310047 from the American Heart Association during the course of this study. The author would like to thank Dr. David Hui for allowing him to complete doctoral research in his laboratory. The author would also like to thank Kimberly Hollie, M.Ed. (wife) and Noah Hollie (son) for their support and understanding through this busy time. Page v Table of Contents List of Figures ............................................................................................................................... vii List of Abbreviations ..................................................................................................................... ix Chapter 1. Introduction ....................................................................................................................1 1. Significance 2. Three obesity-related disorders 3. Treatments for dyslipidemia 4. Normal lipid metabolism 5. Phospholipase A2 6. Metabolic effects of Pla2g1b Chapter 2. Materials and Methods .................................................................................................22 1. Animals 2. Special diets 3. Hepatic VLDL production 4. Postprandial lipid clearance 5. Plasma lipid determination 6. Mitochondrial isolation 7. Mitochondrial swelling 8. Mitochondrial membrane potential 9. Mitochondrial calcium uptake 10. Mitochondrial oxygen consumption 11. Cellular oxygen consumption 12. Hepatocyte viability and mitochondrial permeability transition 13. Determination of atherosclerosis 14. Liver characterization 15. Statistical analysis Chapter 3. Results ..........................................................................................................................39 1. Deficiency of Pla2g1b protects against diet-induced hyperlipidemia 2. Micromolar changes in LPC concentration cause minor effects on hepatic mitochondrial permeability but major alterations in function 3. Inhibition of Pla2g1b protects against selected disorders of lipid metabolism Chapter 4. Discussion ...................................................................................................................58 1. Overview of findings 2. Discussion of “Deficiency of Pla2g1b protects against diet-induced hyperlipidemia” 3. Discussion of “Micromolar changes in LPC concentration cause minor effects on hepatic mitochondrial permeability but major alterations in function” 4. Discussion of “Inhibition of Pla2g1b protects against selected disorders of lipid metabolism” 5. Clinical considerations for inhibition of Pla2g1b References ......................................................................................................................................74 Figures............................................................................................................................................87 Page vi List of Figures 1. Schematic of lipid metabolism through the gut-circulation-liver-adipose axis 2. Responses of Pla2g1b+/+ and Pla2g1b-/- mice to hypercaloric feeding 3. Hepatic VLDL production by Pla2g1b+/+ and Pla2g1b-/- mice 4. Effect of LPC supplementation on hepatic VLDL production by Pla2g1b-/- mice 5. FPLC analysis of 3H radioactivity distribution in plasma subsequent to [3H]LPC injection 6. Postprandial plasma lipid response to a bolus lipid-rich meal 7. Effect of LPC on mitochondrial swelling 8. Effect of LPC on CaCl2-induced mitochondrial swelling 9. Effect of LPC on mitochondrial Ca2+ uptake 10. Effect of LPC on mitochondrial membrane potential 11. Effect of LPC on mitochondrial respiration 12. Effect of LPC on fatty acid-stimulated oxidation in isolated hepatocytes 13. Effect of LPC on hepatocyte mitochondrial permeability in situ 14. Effect of LPC on hepatocyte cytoplasmic activity 15. Effects of diet on body weight of Pla2g1b+/+/Ldlr-/- and Pla2g1b-/-/Ldlr-/- mice 16. Effects of diet on glucose homeostasis in Pla2g1b+/+/Ldlr-/- and Pla2g1b-/-/Ldlr-/- mice 17. Effects of diet on lipoprotein profile of Pla2g1b+/+/Ldlr-/- and Pla2g1b-/-/Ldlr-/- mice 18. Total plasma lipid levels in Pla2g1b+/+/Ldlr-/- and Pla2g1b-/-/Ldlr-/- mice after high fat diet feeding 19. Effect of diet on liver weight of Pla2g1b+/+/Ldlr-/- and Pla2g1b-/-/Ldlr-/- mice 20. Liver histology in high fat fed Pla2g1b+/+/Ldlr-/- and Pla2g1b-/-/Ldlr-/- mice. Page vii 21. Lipid deposition in aortic arch and brachiocephalic artery of Pla2g1b+/+/Ldlr-/- and Pla2g1b-/-/Ldlr-/- mice 22. Atherosclerotic lesion in aortic root of Pla2g1b+/+/Ldlr-/- and Pla2g1b-/-/Ldlr-/- mice 23. Fed state plasma lipid levels in Pla2g1b+/+/Ldlr-/- and Pla2g1b-/-/Ldlr-/- mice after chronic Western
Recommended publications
  • Formulation of Poloxamers for Drug Delivery
    Journal of Functional Biomaterials Review Formulation of Poloxamers for Drug Delivery Andrew M. Bodratti and Paschalis Alexandridis * Department of Chemical and Biological Engineering, University at Buffalo, The State University of New York (SUNY), Buffalo, NY 14260, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-716-645-1183 Received: 18 December 2017; Accepted: 14 January 2018; Published: 18 January 2018 Abstract: Poloxamers, also known as Pluronics®, are block copolymers of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO), which have an amphiphilic character and useful association and adsorption properties emanating from this. Poloxamers find use in many applications that require solubilization or stabilization of compounds and also have notable physiological properties, including low toxicity. Accordingly, poloxamers serve well as excipients for pharmaceuticals. Current challenges facing nanomedicine revolve around the transport of typically water-insoluble drugs throughout the body, followed by targeted delivery. Judicious design of drug delivery systems leads to improved bioavailability, patient compliance and therapeutic outcomes. The rich phase behavior (micelles, hydrogels, lyotropic liquid crystals, etc.) of poloxamers makes them amenable to multiple types of processing and various product forms. In this review, we first present the general solution behavior of poloxamers, focusing on their self-assembly properties. This is followed by a discussion of how the self-assembly properties of poloxamers can be leveraged to encapsulate drugs using an array of processing techniques including direct solubilization, solvent displacement methods, emulsification and preparation of kinetically-frozen nanoparticles. Finally, we conclude with a summary and perspective. Keywords: Pluronic; poly(ethylene oxide); poly(ethylene glycol); nanomedicine; excipient; formulation; solubilization; anticancer; micelle; nanoparticle; hydrogel 1.
    [Show full text]
  • Poloxamer Hydrogels for Biomedical Applications
    pharmaceutics Review Poloxamer Hydrogels for Biomedical Applications Eleonora Russo * and Carla Villa Department of Pharmacy, University of Genoa, Viale Benedetto XV, 16132 Genova, Italy; [email protected] * Correspondence: [email protected] Received: 31 October 2019; Accepted: 6 December 2019; Published: 10 December 2019 Abstract: This review article focuses on thermoresponsive hydrogels consisting of poloxamers which are of high interest for biomedical application especially in drug delivery for ophthalmic, injectable, transdermal, and vaginal administration. These hydrogels remain fluid at room temperature but become more viscous gel once they are exposed to body temperature. In this way, the gelling system remains at the topical level for a long time and the drug release is controlled and prolonged. Poloxamers are synthetic triblock copolymers of poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) (PEO-PPO-PEO), also commercially known as Pluronics®, Synperonics® or Lutrol®. The different poloxamers cover a range of liquids, pastes, and solids, with molecular weights and ethylene oxide–propylene oxide weight ratios varying from 1100 to 14,000 and 1:9 to 8:2, respectively. Concentrated aqueous solutions of poloxamers form thermoreversible gels. In recent years this type of gel has arouse interest for tissue engineering. Finally, the use of poloxamers as biosurfactants is evaluated since they are able to form micelles in an aqueous environment above a concentration threshold known as critical micelle concentration (CMC). This property is exploited for drug delivery and different therapeutic applications. Keywords: poloxamer; hydrogels; micelle; thermosensitive; biomedical; copolymer 1. Introduction The word “hydrogel”, according to Lee, Kwon and Park is due to an article published in 1894, but the first crosslinked network material that appeared in literature and that has been described by its typical hydrogel properties, was a polyhydroxyethylmethacrylate (HEMA) hydrogel developed much later, in 1960, by O.
    [Show full text]
  • Early-Stage Atherosclerosis in Poloxamer 407
    Korolenko et al. Lipids in Health and Disease (2016) 15:16 DOI 10.1186/s12944-016-0186-7 RESEARCH Open Access Early-stage atherosclerosis in poloxamer 407-induced hyperlipidemic mice: pathological features and changes in the lipid composition of serum lipoprotein fractions and subfractions Tatyana A. Korolenko1, Thomas P. Johnston2*, Fedor V. Tuzikov3,4, Natalia A. Tuzikova3,4, Alexandr B. Pupyshev6, Victor K. Spiridonov1, Natalya V. Goncharova1, Igor V. Maiborodin7 and Natalia A. Zhukova5 Abstract Background: The aims of this study were to evaluate the effect of poloxamer 407 administration on atherogenic serum lipoprotein fractions and subfractions associated with cholesterol, triglycerides and phospholipids, as well as the onset of early atherosclerosis, in mice. Methods: Mice were administered either sterile saline or poloxamer 407 (to induce a dose-controlled hyperlipidemia) for 1 month and then sacrificed at 1, 4 and 10 days after the last dose of poloxamer 407. Systolic and diastolic blood pressure, the activity of a cysteine protease (cathepsin B) in cardiac and liver tissue, and histological/morphological examination of heart and liver specimens was performed for each group of mice at each time point. Lastly, small angle X-ray scattering was utilized to analyze the lipoprotein fractions and subfractions associated with cholesterol, triglycerides and phospholipids for both groups of mice at each time point. Statistical analysis was performed using one-way, analysis-of-variance with post hoc analysis to determine significantly different mean values, while correlation analysis employed the Spearman test. Results: Poloxamer 407-treated mice revealed significant hyperlipidemia, moderately elevated blood pressure, general lipidosis in liver cells, increased cysteine protease activity in heart tissue, and contractile-type changes in cardiomyocytes.
    [Show full text]
  • The Importance of Genetic Influences in Asthma
    Copyright #ERS Journals Ltd 1999 Eur Respir J 1999; 14: 1210±1227 European Respiratory Journal Printed in UK ± all rights reserved ISSN 0903-1936 REVIEW The importance of genetic influences in asthma H. Los*,#, G.H. Koppelman*,#, D.S. Postma# The importance of genetic influences in asthma. H. Los, G.H. Koppelman, D.S. Postma. *Dept of Pulmonary Rehabilitation, Bea- #ERS Journals Ltd 1999. trixoord Rehabilitation Centre, Haren, The # ABSTRACT: Asthma is a complex genetic disorder in which the mode of inheritance Netherlands. Dept of Pulmonology, Uni- is not known. Many segregation studies suggest that a major gene could be involved in versity Hospital, Groningen, The Nether- lands. asthma, but until now different genetic models have been obtained. Twin studies, too, have shown evidence for genetic influences in asthma, but have also revealed Correspondence: D.S. Postma substantial evidence for environmental influences, in which nonshared environmental Dept of Pulmonology influences appeared to be important. Linkage, association studies and genome-wide University Hospital Groningen screening suggest that multiple genes are involved in the pathogenesis of asthma. At P.O. Box 30.001 least four regions of the human genome, chromosomes 5q31±33, 6p21.3, 11q13 and 9700 RB Groningen, The Netherlands 12q14.3±24.1, contain genes consistently found to be associated with asthma and Fax: 31 503619320 associated phenotypes. Keywords: Allergy Not only genes associated with asthma but also genes which are involved in the asthma development and outcome of asthma will be found in the future. This will probably genetics provide greater insight into the identification of individuals at risk of asthma and linkage studies early prevention and greater understanding for guiding therapeutic intervention in segregation analysis asthma.
    [Show full text]
  • WO 2016/095083 Al O
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/095083 Al 23 June 2016 (23.06.2016) P O P CT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 8/20 (2006.01) A61K 8/19 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K /27 (2006.01) A61Q 11/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/CN2014/093826 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 15 December 2014 (15. 12.2014) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant: COLGATE-PALMOLIVE COMPANY (84) Designated States (unless otherwise indicated, for every [US/US]; 300 Park Avenue, New York 10022 (US). kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (72) Inventor; and TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant (for SC only): XV, Yun [US/CN]; 338 Qingni- TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, an Road, Xingang Huangpu, GETDD, Guangzhou, Guang DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, dong 510730 (CN).
    [Show full text]
  • Long Noncoding Rnas in Lipid Metabolism
    Long noncoding RNAs in lipid metabolism: literature review and conservation analysis across species Kévin Muret, Colette Désert, Laetitia Lagoutte, Morgane Boutin, Florence Gondret, Tatiana Zerjal, Sandrine Lagarrigue To cite this version: Kévin Muret, Colette Désert, Laetitia Lagoutte, Morgane Boutin, Florence Gondret, et al.. Long noncoding RNAs in lipid metabolism: literature review and conservation analysis across species. BMC Genomics, BioMed Central, 2019, 20, pp.882. 10.1186/s12864-019-6093-3. hal-02387579 HAL Id: hal-02387579 https://hal.archives-ouvertes.fr/hal-02387579 Submitted on 29 Nov 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License Muret et al. BMC Genomics (2019) 20:882 https://doi.org/10.1186/s12864-019-6093-3 REVIEW Open Access Long noncoding RNAs in lipid metabolism: literature review and conservation analysis across species Kevin Muret1, Colette Désert1, Laetitia Lagoutte1, Morgane Boutin1, Florence Gondret1, Tatiana Zerjal2 and Sandrine Lagarrigue1* Abstract Background: Lipids are important for the cell and organism life since they are major components of membranes, energy reserves and are also signal molecules. The main organs for the energy synthesis and storage are the liver and adipose tissue, both in humans and in more distant species such as chicken.
    [Show full text]
  • Influence of Poloxamer 407 on Fractional and Subfractional Composition of Serum Lipoproteins of Mice
    Vol.2, No.7, 722-730 (2010) Health doi:10.4236/health.2010.27110 Influence of poloxamer 407 on fractional and subfractional composition of serum lipoproteins of mice Tatyana A. Korolenko1*, Fedor V. Tuzikov2,3, Thomas P. Johnston4, Natalia A. Tuzikova2,3, Elena E. Filjushina1, Viktoriya M. Loginova1, Natalia G. Savchenko1 1Institute of Physiology, Siberian Branch of Russian Academy of Medical Sciences, Novosibirsk, Russia; *Corresponding Author: [email protected] 2Boreskov Institute of Catalysis, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia 3Novosibirsk State University, Novosibirsk, Russia 4University of Missouri-Kansas City, Kansas City, USA Received 4 March 2010; revised 22 March 2010; accepted 25 March 2010. ABSTRACT Serum Lipoprotein Fractions and Subfractions Using a novel small-angle X-ray scattering (SAXS) method for determination of fractional and sub- 1. INTRODUCTION fractional composition of lipoproteins (LPs), a significant elevation of total cholesterol-lipop- Changes of different classes of circulating lipoproteins roteins (C-LP) and, especially, total triglyceride- are the important indicies of lipid metabolism in physi- lipoproteins (TG-LP), was shown in this work. ology and pathology; lipoproteins have been shown to Among the LP fractions, poloxamer 407 was also play a regulatory role in vivo [1,2]. The main lipo- shown to significantly increase proatherogenic protein classes consist of pro-atherogenic low-density li- total C-LDL, TG-LDL and, especially, their pre- poproteins (LDL), very-low-density lipoproteins (VLDL), cursors C-VLDL and TG-VLDL, while only ex- and anti-atherogenic high density lipoproteins (HDL), hibiting a moderate increase in the antiathero- and are widely used as common lipid biomarkers in genic C-HDL and TG-HDL fractions.
    [Show full text]
  • Competitive Comparison 3M™ Clinpro™ Toothpaste
    Competitive Comparison 3M™ Clinpro™ Toothpaste Fluoride Calcium Rx Is it a Product Size Flavors Type and Phosphate Full Ingredient List Manufacturer’s Claims Required? Toothpaste? Concentration Based Additive Manufactured by 3M • Clinically proven prescription-strength toothpaste • Remineralizes lesions throughout— not just on the surface • Delivers more fluoride to the tooth than other leading brands tested • Contains 1.1.% NaF (5000ppm fluoride ion) Sodium fluoride, water, sorbitol, hydrated silica, 3M™ Clinpro™ Functionalized • Contains tri-calcium phosphate ingredient (TCP), Vanilla Mint, 1.1% Sodium glycerin, polyethylene-polypropylene glycol, 5000 4oz Tricalcium so Clinpro 5000 toothpaste releases a high Yes Yes Spearmint, Fluoride flavor, polyethylene glycol, sodium lauryl sulfate, Anti-Cavity (113g) Phosphate level of fluoride plus calcium and phosphate— Bubble Gum (5000ppm) titanium dioxide, carboxymethyl cellulose, Toothpaste (fTCP) components found naturally in saliva sodium saccharin and tri-calcium phosphate • Gentle cleaning, gentle whitening • Low abrasion • Use once daily in place of a conventional toothpaste • Available in a convenient 4oz flip-top tube (approx. 6-month patient supply) • Strengthens teeth better than leading brands • Lower fluoride, no prescription needed • Exclusive formula protects against cavities Sodium fluoride, water, sorbitol, hydrated silica, 3M™ Clinpro™ Functionalized and helps reverse white spots 0.21% Sodium glycerin, polyethylene-polypropylene glycol, Tooth Crème 4oz Tricalcium • Perfect for patients at moderate or high risk No Yes Vanilla Mint Fluoride flavor, polyethylene glycol, sodium lauryl sulfate, Anti-Cavity (113g) Phosphate of dental cavities (950ppm) titanium dioxide, carboxymethyl cellulose, Toothpaste (fTCP) sodium saccharin and tri-calcium phosphate • Cleans and whitens teeth with low abrasion • Contains fluoride as well as calcium and phosphate, which are components naturally found in saliva Information available on competitive websites as of March 2019.
    [Show full text]
  • Screening Differentially Expressed Genes of Pancreatic Cancer
    Xu et al. BMC Cancer (2020) 20:298 https://doi.org/10.1186/s12885-020-06722-7 RESEARCH ARTICLE Open Access Screening differentially expressed genes of pancreatic cancer between Mongolian and Han people using bioinformatics technology Jiasheng Xu1†, Kaili Liao2†, Zhonghua Fu3* and Zhenfang Xiong1* Abstract Background: To screen and analyze differentially expressed genes in pancreatic carcinoma tissues taken from Mongolian and Han patients by Affymetrix Genechip. Methods: Pancreatic ductal cell carcinoma tissues were collected from the Mongolian and Han patients undergoing resection in the Second Affiliated Hospital of Nanchang University from March 2015 to May 2018 and the total RNA was extracted. Differentially expressed genes were selected from the total RNA qualified by Nanodrop 2000 and Agilent 2100 using Affymetrix and a cartogram was drawn; The gene ontology (GO) analysis and Pathway analysis were used for the collection and analysis of biological information of these differentially expressed genes. Finally, some differentially expressed genes were verified by real-time PCR. Results: Through the microarray analysis of gene expression, 970 differentially expressed genes were detected by comparing pancreatic cancer tissue samples between Mongolian and Han patients. A total of 257 genes were significantly up-regulated in pancreatic cancer tissue samples in Mongolian patients; while a total of 713 genes were down-regulated. In the Gene Ontology database, 815 differentially expressed genes were identified with clear GO classification, and CPB1 gene showed the highest increase in expression level (multiple difference: 31.76). The pathway analysis detected 28 signaling pathways that included these differentially expressed genes, involving a total of 178 genes. Among these pathways, the enrichment of differentially expressed genes in the FAK signaling pathway was the strongest and COL11A1 gene showed the highest multiple difference (multiple difference: 5.02).
    [Show full text]
  • US5407445.Pdf
    ||||||||||||||||| USOO5407445A United States Patent (19) 11 Patent Number: 5,407,445 Tautvydas et al. 45 Date of Patent: Apr. 18, 1995 54 GEL COMPOSITION FOR IMPLANT 4,790,848 12/1988 Cronin . PROSTHESIS AND METHOD OF USE 4,795,463 1/1989 Gerow . 4,820,302 4/1989 Woodroof. 75 Inventors: Daiva K. Tautvydas, Atlanta; 4,820,303 4/1989 Brauman . Mannarsamy Balasubramanian, 4,822,741 4/1989 Bares . Roswell; R. Martin Emanuele, 4,828,561 5/1989 Woodroff. Alpharetta, all of Ga. 4,839,280 6/1989 Bares . 73 Assignee: Cytrk Corporation, Norcross, Ga. s: $3. kistan. 21 Appl. No.: 64,519 4,912,141 3/1990 Kronman , 4,936,858 6/1990 O'Keeffe . 22 Filed: May 19, 1993 4,955,909 9/1990 Ersek et al. 4,963,150 10/1990 Brauman . Related U.S. Application Data 4,995,882 2/1991. Destouet et al. a 5,019, 100 5/1991 Hennink et al. (63) in part of Ser. No. 886,264, May 20, 5,067,965 11/1991 Ersek et al. s 5,120,816 6/1992 Gould et al. 51) Int. Cl. ................................................ A61F 2/12 52 U.S. C. .......................................... 623/8; 623/11; OTHER PUBLICATIONS 623/66 Touchette, N., “Research. In Focus-Silicone Implants 58 Field of Search ............... 623/11, 16, 66; 528/76; and Autoimmune Disease: Studies Fail to Gel, The 424/422 Journal of NIH Research, vol. 4, pp.49-52 (May 1992). Gladwell, M., “FDA Wii Allow Limited Use of 56 References Cited Silicone-Gel Breast Implants', the Washington Post, U.S.
    [Show full text]
  • A Thesis Entitled the Preparation and Characterization of Poloxamer
    A Thesis entitled The Preparation and Characterization of Poloxamer-Based Temperature-Sensitive Hydrogels for Topical Drug Delivery. By Sarath Chandra Reddy Gandra Submitted to the Graduate Faculty as partial fulfillment of the requirements for The Master of Science Degree in Pharmaceutical Sciences with Industrial Pharmacy option Jerry Nesamony, Ph.D., Committee Chair Kenneth Alexander, Ph.D., Committee Member Sai Hanuman Sagar Boddu, Ph.D., Committee Member Dr. Patricia Komuniecki, Ph.D., Dean College of Graduate Studies The University of Toledo August 2013 Copyright © 2013 This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of The Preparation and Characterization of Poloxamer-Based Temperature-Sensitive Hydrogels for Topical Drug Delivery. by Sarath Chandra Reddy Gandra Submitted to Graduate Faculty as partial fulfillment of the requirements for The Master of Science Degree in Pharmaceutical Sciences with Industrial Pharmacy option The University of Toledo August 2103 Stimuli-sensitive hydrogels change their swelling behavior and drug release by sensing changes in the surrounding environment. One example is temperature-sensitive hydrogels which change their swelling behavior in response to a change in the environmental temperature. Poloxamers are tri-block copolymers that exhibit thermoreversible properties by transforming from a liquid-like behavior to gel-like behavior above a certain temperature called sol-gel transition temperature. By varying the concentration of poloxamer and other excipients, hydrogels with sol-gel transition point close to body temperature can be achieved. The aim of the present study was to develop poloxamer hydrogels as in situ gelling formulation for topical drug delivery.
    [Show full text]
  • Enhancement of the Rate of Solution of Relatively Insoluble Drugs from Solid-Solid Systems Prepared by Supercritical Fluid Technology
    ENHANCEMENT OF THE RATE OF SOLUTION OF RELATIVELY INSOLUBLE DRUGS FROM SOLID-SOLID SYSTEMS PREPARED BY SUPERCRITICAL FLUID TECHNOLOGY DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Carmen H. Ramirez, M.S. * * * * * The Ohio State University 2007 Dissertation Committee: Approved by Professor Sylvan G. Frank, Advisor Professor William L. Hayton Professor James T. Dalton ________________________ Advisor Professor Robert W. Curley Graduate Program in Pharmacy Copyright by Carmen H. Ramirez 2007 ABSTRACT Supercritical fluid technology, specifically the method of rapid expansion of supercritical solutions (RESS), has been used to prepare small particles consisting of solid solutions of a relatively insoluble drug and a water-soluble excipient. With an increasing number of relatively insoluble compounds being discovered, a general process for enhancing drug dissolution rates would assist formulation of these compounds for therapeutic use. Solid solutions could serve as a means for enhancing drug dissolution rates, since the drug is dispersed in a solid solvent in its smallest form, i.e., a molecule, prior to entering into solution. Therefore, solid solutions consisting of the relatively insoluble model drugs lidocaine or probucol and a water-soluble surfactant, poloxamers 407, 188, or 403 were prepared by RESS processing. Dissolution studies of these systems were performed and evaluated for their ability to enhance drug release rates. Furthermore, the mechanism by which solid solutions form in these systems was determined using differential scanning calorimetry (DSC) and Fourier transform infrared (FTIR) spectroscopy. Scanning electron microscopy (SEM) was also used to study the surface characteristics of these particulate systems.
    [Show full text]